Document 0355
 DOCN  M9550355
 TI    CD30 (Ki-1)-positive anaplastic large-cell lymphomas in 13 patients with
       and 27 patients without human immunodeficiency virus infection: the
       first comparative clinicopathologic study from a single institution that
       also includes 80 patients with other human immunodeficiency
       virus-related systemic lymphomas.
 DT    9505
 AU    Tirelli U; Vaccher E; Zagonel V; Talamini R; Bernardi D; Tavio M;
       Gloghini A; Merola MC; Monfardini S; Carbone A; Division of Medical
       Oncology and AIDS, Cancer Center, Aviano,; Italy.
 SO    J Clin Oncol. 1995 Feb;13(2):373-80. Unique Identifier : AIDSLINE
       MED/95147021
 AB    PURPOSE: CD30 (Ki-1)-positive anaplastic large-cell lymphoma (Ki-1 ALCL)
       rarely has been described in patients with human immunodeficiency virus
       (HIV) infection. The purpose of this study was to characterize further
       the clinicopathologic features of Ki-1 ALCL in patients with HIV
       infection and, for the first time, to make a comparison with Ki-1 ALCL
       in patients without HIV infection. PATIENTS AND METHODS: From September
       1987 to April 1993, 93 patients with HIV infection and systemic
       non-Hodgkin's lymphoma (NHL) were treated at the Cancer Center of
       Aviano, Italy; in 13 (14%), the diagnosis was of Ki-1 ALCL subtype. This
       group of patients was compared with the remaining 80 patients who had
       other HIV-related NHL and with another group of 27 patients with Ki-1
       ALCL who were without a diagnosis of HIV infection. RESULTS: There was
       no case of a T-cell phenotype in the 13 HIV-positive Ki-1 ALCL patients,
       whereas there was such a phenotype in six of 27 (22%) HIV-negative Ki-1
       ALCL patients. In regard to the general characteristics of the two
       groups with Ki-1 ALCL, more patients with stage IV, two or more
       extranodal sites at presentation, treatment-related leukopenia, and
       opportunistic infections as the cause of death were observed in the
       HIV-positive Ki-1 ALCL group. When these variables were compared with
       those of the other HIV-related NHL group, such differences were not
       present. CONCLUSION: Ki-1 ALCL is not a rare clinicopathologic entity
       among NHL in patients with HIV infection. The differences observed
       within the two Ki-1 ALCL groups of patients may be because of factors
       related to the HIV infection alone.
 DE    Adult  Antineoplastic Agents, Combined/THERAPEUTIC USE  Cause of Death
       Comparative Study  Doxorubicin/THERAPEUTIC USE  Female  Human  HIV
       Infections/*COMPLICATIONS/DIAGNOSIS  Immunophenotyping  Lymphoma,
       Large-Cell, Ki-1/*COMPLICATIONS/PATHOLOGY/THERAPY  Lymphoma,
       Non-Hodgkin's/*COMPLICATIONS/PATHOLOGY/THERAPY  Male  Middle Age
       Support, Non-U.S. Gov't  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).